The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy
Open accessAbstract
Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is overexpressed across a wide range of tumors. Disialoganglioside GD2 can be considered a tumor-associated antigen and well-suited as a target for cancer therapy. Disialoganglioside GD2 is implicated in tumor development and malignant phenotypes through enhanced cell proliferation, motility, migration, adhesion, and invasion, depending on the tumor type. This provides a rationale for targeting disialoganglioside GD2 in cancer therapy with the development of anti-GD2 monoclonal antibodies and other therapeutic approaches. Anti-GD2 monoclonal antibodies target GD2-expressing tumor cells, leading to phagocytosis and destruction by means of antibody-dependent cell-mediated cytotoxicity, lysis by complement-dependent cytotoxicity, and apoptosis and necrosis through direct induction of cell death. Anti-GD2 monoclonal antibodies may also prevent homing and adhesion of circulating malignant cells to the extracellular matrix. Disialoganglioside GD2 is highly expressed by almost all neuroblastomas, by most melanomas and retinoblastomas, and by many Ewing sarcomas and, to a more variable degree, by small cell lung cancer, gliomas, osteosarcomas, and soft tissue sarcomas. Successful treatment of disialoganglioside GD2-expressing tumors with anti-GD2 monoclonal antibodies is hindered by pharmacologic factors such as insufficient antibody affinity to mediate antibody-dependent cell-mediated cytotoxicity, inadequate penetration of antibody into the tumor microenvironment, and toxicity related to disialoganglioside GD2 expression by normal tissues such as peripheral sensory nerve fibers. Nonetheless, anti-GD2 monoclonal antibody dinutuximab (ch14.18) has been approved by the U.S. Food and Drug Administration and dinutuximab beta (ch14.18/CHO) has been approved by the European Medicines Agency for the treatment of high-risk neuroblastoma in pediatric patients. Clinical trials of anti-GD2 therapy are currently ongoing in patients with other types of disialoganglioside GD2-expressing tumors as well as neuroblastoma. In addition to anti-GD2 monoclonal antibodies, anti-GD2 therapeutic approaches include chimeric antigen receptor T-cell therapy, disialoganglioside GD2 vaccines, immunocytokines, immunotoxins, antibody-drug conjugates, radiolabeled antibodies, targeted nanoparticles, and T-cell engaging bispecific antibodies. Clinical trials should clarify further the potential of anti-GD2 therapy for disialoganglioside GD2-expressing malignant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroblastoma: biological insights into a clinical enigma
Brodeur, G. M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1014 · Cited by 2,160
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
CHROMATOGRAPHlC SEPARATION OF HUMAN BRAIN GANGLIOSIDES*
Svennerholm, L. (1963) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1963.tb08933.x · Cited by 1,643
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
van Die, I. (2017) · Pure Amsterdam UMC · Cited by 1,112
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
Mount, C. W., Majzner, R. G., Sundaresh, S., Arnold, E. P., Kadapakkam, M., Haile, S., Labanieh, L., Hulleman, E., Woo, P. J., Rietberg, S. P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0006-x · Cited by 499
Ladenstein, R., Pötschger, U., Valteau-Couanet, D., Luksch, R., Castel, V., Yaniv, I., Laureys, G., Brock, P., Michon, J. M., Owens, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30578-3 · Cited by 418
Cheung, N. K., Lazarus, H., Miraldi, F. D., Abramowsky, C. R., Kallick, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., & Berger, N. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1430 · Cited by 417
Structures, Biosynthesis, and Functions of Gangliosides-an Overview
Yu, R. K., Tsai, Y.-T., Ariga, T., & Yanagisawa, M. (2011) · Journal of Oleo Science · doi:10.5650/jos.60.537 · Cited by 416
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
Schulz, G., Cheresh, D. A., Varki, N. M., Yu, A. L.-T., Staffileno, L. K., & Reisfeld, R. A. (1984) · PubMed · Cited by 368
Cheresh, D. A., Pierschbacher, M. D., Herzig, M. A., & Mujoo, K. (1986) · The Journal of cell biology · doi:10.1083/jcb.102.3.688 · Cited by 313
Gangliosides in cell recognition and membrane protein regulation
Lopez, P. H., & Schnaar, R. L. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.06.001 · Cited by 311
Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis
Battula, V. L., Shi, Y., Evans, K. W., Wang, R.-Y., Spaeth, E. L., Jacamo, R. O., Guerra, R., Sahin, A. A., Marini, F. C., Hortobagyi, G., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59735 · Cited by 302
Zhang, S., Cordon-Cardo, C., Zhang, H. S., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O., & Livingston, P. O. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<42::aid-ijc8>3.0.co;2-1 · Cited by 280
Mody, R., Naranjo, A., Van Ryn, C., Yu, A. L., London, W. B., Shulkin, B. L., Parisi, M. T., Servaes, S.-E.-N., Diccianni, M. B., Sondel, P. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30355-8 · Cited by 277
Richman, S. A., Nunez-Cruz, S., Moghimi, B., Li, L. Z., Gershenson, Z. T., Mourelatos, Z., Barrett, D. M., Grupp, S. A., & Milone, M. C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0211 · Cited by 267
Cheung, N.-K. V., Cheung, I. Y., Kushner, B. H., Ostrovnaya, I., Chamberlain, E., Kramer, K., & Modak, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.3807 · Cited by 263
Mujoo, K., Cheresh, D. A., Yang, H. M., & Reisfeld, R. A. (1987) · PubMed · Cited by 246
Perforin: an important player in immune response
Osińska, I., Popko, K., & Demkow, U. (2014) · Central European Journal of Immunology · doi:10.5114/ceji.2014.42135 · Cited by 214
Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., Reuland, P., Gillies, S. D., Reisfeld, R. A., & Niethammer, D. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00413-y · Cited by 213
Anti-GD2 immunotherapy for neuroblastoma
Sait, S., & Modak, S. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1364995 · Cited by 210
Xu, X., Huang, W., Heczey, A., Liu, D., Guo, L., Wood, M., Jin, J., Courtney, A. N., Liu, B., Di Pierro, E. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0421 · Cited by 192
Ozkaynak, M. F., Sondel, P. M., Krailo, M. D., Gan, J., Javorsky, B., Reisfeld, R. A., Matthay, K. K., Reaman, G. H., & Seeger, R. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4077 · Cited by 190
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody.
Mueller, B. M., Romerdahl, C. A., Gillies, S. D., & Reisfeld, R. A. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.144.4.1382 · Cited by 186
Neuroblastoma Origin and Therapeutic Targets for Immunotherapy
Kholodenko, I. V., Kalinovsky, D. V., Doronin, I. I., Deyev, S. M., & Kholodenko, R. V. (2018) · Journal of Immunology Research · doi:10.1155/2018/7394268 · Cited by 185
Yoshida, S., Fukumoto, S., Kawaguchi, H., Sato, S., Ueda, R., & Furukawa, K. (2001) · PubMed · Cited by 178
CAR T Cell Therapy for Neuroblastoma
Richards, R. M., Sotillo, E., & Majzner, R. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02380 · Cited by 168
Ganglioside GD2 as a therapeutic target for antibody‐mediated therapy in patients with osteosarcoma
Roth, M., Linkowski, M., Tarim, J., Piperdi, S., Sowers, R., Geller, D., Gill, J., & Gorlick, R. (2014) · Cancer · doi:10.1002/cncr.28461 · Cited by 167
Disialoganglioside GD2 as a therapeutic target for human diseases
Suzuki, M., & Cheung, N. V. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.986459 · Cited by 156
Mujoo, K., Kipps, T. J., Yang, H., et al. (1989) · PubMed · Cited by 155
Engineering anti‐GD2 monoclonal antibodies for cancer immunotherapy
Ahmed, M., & Cheung, N. V. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.030 · Cited by 154
Dinutuximab: First Global Approval
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0399-5 · Cited by 147
Kushner, B. H., Cheung, I. Y., Modak, S. I., Kramer, K., Ragupathi, G., & Cheung, N. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1012 · Cited by 147
Kailayangiri, S., Altvater, B., Meltzer, J., Pscherer, S., Luecke, A., Dierkes, C., Titze, U., Leuchte, K., Landmeier, S., Hotfilder, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.57 · Cited by 146
Simon, T., Hero, B., Faldum, A., Handgretinger, R., Schrappe, M., NIETHAMMER, D., & Berthold, F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.143 · Cited by 141
Shed tumor gangliosides and progression of human neuroblastoma
Valentino, L., Moss, T., Olson, E., Wang, H., Elashoff, R., & Ladisch, S. (1990) · Blood · doi:10.1182/blood.v75.7.1564.1564 · Cited by 138
Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Navid, F., Santana, V. M., & Barfield, R. C. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791054167 · Cited by 135
Tran, H. C., Wan, Z., Sheard, M. A., Sun, J., Jackson, J. R., Malvar, J., Xu, Y., Wang, L. W., Sposto, R., Kim, E. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1743 · Cited by 134
Kushner, B. H., Cheung, I. Y., Modak, S. I., Basu, E. M., Roberts, S. S., & Cheung, N. V. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4005 · Cited by 132
Cheung, N. V., Landmeier, B. J., Neely, J. E., Nelson, A. D., Abramowsky, C. R., Ellery, S., Adams, R. B., & Miraldi, F. D. (1986) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/77.3.739 · Cited by 118
Molecular Recognition of Gangliosides and Their Potential for Cancer Immunotherapies
Krengel, U., & Bousquet, P. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00325 · Cited by 115
Aixinjueluo, W., Furukawa, K., Zhang, Q., Hamamura, K., Tokuda, N., Yoshida, S., Ueda, R., & Furukawa, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414041200 · Cited by 110
Liu, Y., Wu, H.-W., Sheard, M. A., Sposto, R., Somanchi, S. S., Cooper, L. J. N., Lee, D. A., & Seeger, R. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1243 · Cited by 110
Alvarez-Rueda, N., Desselle, A., Cochonneau, D., Chaumette, T., Clemenceau, B., Leprieur, S., Bougras-Cartron, G., Supiot, S., Mussini, J. M., Barbet, J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025220 · Cited by 107
Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma.
Heiner, J., Miraldi, F. D., Kallick, S., Makley, J. T., Neely, J. E., Smith-Mensah, W. H., & Cheung, N. V. (1987) · PubMed · Cited by 106
Ganglioside GD2 in reception and transduction of cell death signal in tumor cells
Doronin, I. I., Vishnyakova, P., Kholodenko, I. V., Ponomarev, E. D., Ryazantsev, D. Y., Molotkovskaya, I. M., & Kholodenko, R. V. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-295 · Cited by 106
Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: Direct interaction of GM3 with VEGFR-2
Chung, T., Kim, S.-J., Choi, H., Kim, K.-J., Kim, M., Kim, S., Lee, H., Ko, J. H., Lee, Y., Suzuki, A., et al. (2008) · Glycobiology · doi:10.1093/glycob/cwn114 · Cited by 104
Targeting GD2-positive glioblastoma by chimeric antigen receptor empowered mesenchymal progenitors
Golinelli, G., Grisendi, G., Prapa, M., Bestagno, M., Spano, C., Rossignoli, F., Bambi, F., Sardi, I., Cellini, M., Horwitz, E. M., et al. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0062-x · Cited by 98
Cheresh, D. A., & Klier, F. G. (1986) · The Journal of Cell Biology · doi:10.1083/jcb.102.5.1887 · Cited by 96
Agarwal, S., Lakoma, A., Chen, Z., Hicks, J. M., Metelitsa, L. S., Kim, E. S., & Shohet, J. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2946 · Cited by 96
Furman, W. L., Federico, S. M., McCarville, M. B., Shulkin, B. L., Davidoff, A. M., Krasin, M. J., Sahr, N. A., Sykes, A. D., Wu, J., Brennan, R. C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1452 · Cited by 96
Seitz, C. M., Schroeder, S. M., Knopf, P., Krahl, A.-C., Hau, J., Schleicher, S., Martella, M., Quintanilla‐Martínez, L., Kneilling, M., Pichler, B. J., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1683345 · Cited by 96
Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma
Vanichapol, T., Chutipongtanate, S., Anurathapan, U., & Hongeng, S. (2018) · BioMed Research International · doi:10.1155/2018/1812535 · Cited by 90
GD2-Targeted Immunotherapy and Radioimmunotherapy
Dobrenkov, K., & Cheung, N. V. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.07.003 · Cited by 84
Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors
Cavdarli, S., Groux‐Degroote, S., & Delannoy, P. (2019) · Biomolecules · doi:10.3390/biom9080311 · Cited by 84
Keyel, M. E., & Reynolds, C. P. (2018) · Biologics · doi:10.2147/btt.s114530 · Cited by 82
Bailey, K. M., Cost, C. R., Davis, I. J., Bender, J. G., Grohar, P. J., Houghton, P. J., Isakoff, M. S., Stewart, E. S., Laack, N. N., Yustein, J. T., et al. (2019) · F1000Research · doi:10.12688/f1000research.18139.1 · Cited by 79
Terzić, T., Cordeau, M., Herblot, S., Teira, P., Cournoyer, S., Beaunoyer, M., Peuchmaur, M. M., Duval, M., & Sartelet, H. (2017) · Pediatric and Developmental Pathology · doi:10.1177/1093526617723972 · Cited by 77
Anti-GD2 MABS and Next-Generation mAb-Based Agents for Cancer Therapy
Horta, Z. P., Goldberg, J. L., & Sondel, P. M. (2016) · Immunotherapy · doi:10.2217/imt-2016-0021 · Cited by 74
Andersch, L., Radke, J., Klaus, A., Schwiebert, S., Winkler, A., Schumann, E., Grunewald, L., Zirngibl, F., Flemmig, C., Jensen, M. C., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6131-1 · Cited by 74
Differential roles of gangliosides in malignant properties of melanomas
Ohmi, Y., Kambe, M., Ohkawa, Y., Hamamura, K., Tajima, O., Takeuchi, R., Furukawa, K., & Furukawa, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206881 · Cited by 69
Enhancement of malignant properties of human glioma cells by ganglioside GD3/GD2
Iwasawa, T., Zhang, P., Ohkawa, Y., Momota, H., Wakabayashi, T., Ohmi, Y., Bhuiyan, R. H., Furukawa, K., & Furukawa, K. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4266 · Cited by 67
Uttenreuther-Fischer, M. M., Huang, C.-S., & Yu, A. L.-T. (1995) · Cancer Immunology Immunotherapy · doi:10.1007/bf01526552 · Cited by 63
GD2 expression in breast cancer
Orsi, G., Barbolini, M., Ficarra, G., Tazzioli, G., Manni, P., Petrachi, T., Mastrolia, I., Orvieto, E., Spano, C., Prapa, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16363 · Cited by 63
Esaki, N., Ohkawa, Y., Hashimoto, N., Tsuda, Y., Ohmi, Y., Bhuiyan, R. H., Kotani, N., Honke, K., Enomoto, A., Takahashi, M., et al. (2017) · Cancer Science · doi:10.1111/cas.13448 · Cited by 59
Charan, M., Dravid, P., Cam, M., Audino, A., Gross, A. C., Arnold, M. A., Roberts, R. D., Cripe, T. P., Pertsemlidis, A., Houghton, P. J., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32743 · Cited by 59
Barry, W. E., Jackson, J. R., Asuelime, G. E., Wu, H., Sun, J., Wan, Z., Malvar, J., Sheard, M. A., Wang, L. L., Seeger, R. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1317 · Cited by 58
The ganglioside GD2 as a circulating tumor biomarker for neuroblastoma
Balis, F. M., Busch, C. M., Desai, A. V., Hibbitts, E., Naranjo, A. H., Bagatell, R., Irwin, M. S., & Fox, E. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28031 · Cited by 58
Anti-idiotypic antibodies as cancer vaccines: achievements and future improvements
Ladjemi, M. Z. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00158 · Cited by 54
Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer
Vantaku, V., Donepudi, S. R., Ambati, C. R., Jin, F., Putluri, V., Nguyen, K., Rajapakshe, K., Coarfa, C., Battula, V. L., Lotan, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21038 · Cited by 53
The Promise of Anti-idiotype Revisited
Köhler, H., Pashov, A. D., & Kieber‐Emmons, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00808 · Cited by 50
Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma
Mora, J. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1160775 · Cited by 48
Glycobiology of Neuroblastoma: Impact on Tumor Behavior, Prognosis, and Therapeutic Strategies
Berois, N., & Osinaga, E. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00114 · Cited by 47
Tumor gangliosides accelerate murine tumor angiogenesis
Liu, Y., Wondimu, A., Yan, S., Bobb, D., & Ladisch, S. (2013) · Angiogenesis · doi:10.1007/s10456-013-9403-4 · Cited by 44
TargetingO-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
Fleurence, J., Fougeray, S., Bahri, M., Cochonneau, D., Clemenceau, B., Paris, F., Heczey, A. A., & Birklé, S. (2017) · Journal of Immunology Research · doi:10.1155/2017/5604891 · Cited by 44
Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
Casey, D. L., Lin, T.-Y., & Cheung, N. V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00537 · Cited by 44
Sujjitjoon, J., Sayour, E. J., Tsao, S.-T., Uiprasertkul, M., Sanpakit, K., Buaboonnam, J., Yenchitsomanus, P., Atchaneeyasakul, L., & Chang, L. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100971 · Cited by 41
Tivnan, A., Heilinger, T., Ramsey, J. M., O’Connor, G., Pokorny, J. L., Sarkaria, J. N., Stringer, B. W., Day, B. W., Boyd, A., Kim, E. L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15073 · Cited by 40
Butch, E. R., Mead, P. E., Diaz, V. A., Sheppard, H., Stewart, E. A., Mishra, J. K., Kim, J.-E., Bahrami, A., Dearling, J. L. J., Packard, A. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3340 · Cited by 34
Shusterman, S., Naranjo, A. H., Ryn, C. V., Hank, J. A., Parisi, M. T., Shulkin, B. L., Servaes, S. E., London, W. B., Shimada, H., Gan, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0798 · Cited by 34
Gangliosides in Neuroblastomas
Schengrund, C., & Shochat, S. J. (1988) · Neurochemical Pathology · doi:10.1007/bf03160146 · Cited by 31
Gallo, O., Bani, D., Toccafondi, G., Alnzerigogna, F., & Storchi, O. F. (1992) · Cancer · doi:10.1002/1097-0142(19920801)70:3<633::aid-cncr2820700315>3.0.co;2-f · Cited by 30
Tong, W., Maira, M., Gagnon, M., & Saragovi, H. U. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134255 · Cited by 27
Siebert, N., Seidel, D., Eger, C., Jüttner, M., & Lode, H. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107692 · Cited by 27
Carvajal, R. D., Agulnik, M., Ryan, C. W., Milhem, M. M., George, S., Jones, R. L., Chmielowski, B., Tine, B. A. V., Tawbi, H. A.-H., ELIAS, A. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.10520 · Cited by 21
Druker, B. J., Rosenthal, D. S., & Canellos, G. P. (1989) · Cancer · doi:10.1002/1097-0142(19890315)63:6<1166::aid-cncr2820630621>3.0.co;2-5 · Cited by 18
Zhu, W., Mao, X., Wang, W., Chen, Y., Li, D., Li, H., & Dou, P. (2018) · Die Pharmazie · doi:10.31083/ph.2018.7836 · Cited by 18
Shen, H., Tang, Y., Xu, X., & Tang, H. (2012) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2012.737094 · Cited by 13
Pennington, B., Ren, S., Barton, S., Bacelar, M., & Edwards, S. J. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0744-0 · Cited by 13
Soman, G., Kallarakal, A. T., Michiel, D. F., Yang, X., Saptharish, N., Jiang, H., Giardina, S. L., Gilly, J. A., & Mitra, G. (2012) · mAbs · doi:10.4161/mabs.4.1.18566 · Cited by 11
Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer
Chen, L., Brown, A. B., Cheung, I. Y., Cheung, N. V., Kris, M. G., & Krug, L. M. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.009 · Cited by 10
Ari, P., Kars, M. S., Meany, H. J., & Pestieau, S. R. (2017) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000889 · Cited by 10
Cited by
Agliardi, G., Liuzzi, A. R., Hotblack, A., De Feo, D., Núñez, N., Stowe, C. L., Friebel, E., Nannini, F., Rindlisbacher, L., Roberts, T. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20599-x · Cited by 305
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors
Quamine, A. E., Olsen, M. R., Cho, M. M., & Capitini, C. M. (2021) · Cancers · doi:10.3390/cancers13112796 · Cited by 39
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
Metadata
- Authors
- Nazha, B., Inal, C., & Owonikoko, T. K.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-07-07
- Volume
- 10
- Pages
- 1000-1000
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3041156479
- Cited by
- 324
- References
- 93
- FWCI
- 10.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.